Trials / Withdrawn
WithdrawnNCT04807829
Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation
A Randomized-Controlled Trial With the Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nabilone | Nabilone is a synthetic endocannabinoid and CB1 agonist. |
| DRUG | Placebo | Inactive placebo comparator |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2021-03-19
- Last updated
- 2021-09-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04807829. Inclusion in this directory is not an endorsement.